"I can't help wondering if there were flaws in the preliminary studies design that led to over estimation of accuracy."
There are two key differences between the studies:
1. Australian study using the inventor to evaluate the results.
2. US study using double blind trials with three of the best hospitals in the world.
RAP want us to believe that study 1 was kosher, and study 2 was mishandled.
Hmmmmmm.
- Forums
- ASX - By Stock
- RAP
- Ann: Investor Conference Call
Ann: Investor Conference Call, page-57
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online